PCSK9 and metabolic dysfunction-associated steatotic liver disease: As a consequence, drugs administered to prevent hypertriglyceridemia (fibrates, omega-3-fatty acids), hypercholesterolemia (statins, ezetimibe, Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, lomitapide, and bile acid sequestrants) [12] and IR (metformin, sulfonylureas and thiazolidinediones, dipeptidyl peptidase-4 inhibitors and incretins) [13] have all shown to ameliorate hepatic dysfunctions caused by NAFLD [3,14].